Trial Profile

Phase 1/2 antibody-drug conjugate (ADC) combination trial with CR-001

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CR 002 (Primary) ; CR-001-Crescent Biopharma (Primary) ; CR-003 (Primary) ; Immunoconjugates (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

06 Mar 2026 New trial record
26 Feb 2026 According to Crescent Biopharma media release, readouts expected in year end 2027
26 Feb 2026 According to Crescent Biopharma media release, three more trials are on track to initiate this year. since, more details not available, retained only one trial for now.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com